Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
NCT01584934 · University Hospital, Ghent · PHASE4 · withdrawn · last registry update 2022-12-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “incompatibilities over intellectual property” | – | Registry record, University Hospital, Ghent |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-04Phase 3 first posted: Nationwide Children's Hospital, Baclofen + Placebo (NCT05975684)
- 2023-07-07Phase 3 first posted: Hospices Civils de Lyon, Baclofen 30 mg + Baclofen 60 mg (NCT05935553)
- 2023-06-27Phase 3 first posted: Tanta University, Baclofen 10mg + Gabapentin (NCT05921604)
- 2023-05-10Results posted on the registry: Stanford University, Sodium Oxybate (NCT04006925)
- 2022-09-28Results posted on the registry: Baylor College of Medicine, sodium oxybate (NCT00641186)
- 2022-08-26Phase 3 first posted: Tanta University, Baclofen Tablets (NCT05516953)
- 2022-07-15Results posted on the registry: RVL Pharmaceuticals, Inc., Arbaclofen (NCT03319732)
- 2022-07-15Results posted on the registry: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT03290131)
- 2022-04-29Also stopped (terminated): Mansoura University, Orphenadrine + Baclofen (NCT04509336)
- 2022-04-27Also stopped (withdrawn): RVL Pharmaceuticals, Inc., arbaclofen ER Tablets + Placebo for arbaclofen ER tablets (NCT02869425)
- 2022-04-08Results posted on the registry: UCB Pharma SA, Sodium Oxybate (Xyrem) (NCT00345800)
- 2022-03-22Results posted on the registry: Avadel, FT218 + Placebo (NCT02720744)
- 2022-01-05Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT05179577)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision